Matching articles for "Ozempic"
In Brief: Higher-Dose Semaglutide (Ozempic) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 16, 2022; (Issue 1650)
The FDA has approved a higher-dose injectable
formulation of the long-acting glucagon-like
peptide-1 (GLP-1) receptor agonist semaglutide
(Ozempic) for treatment of type 2 diabetes in adults.
A single SC...
The FDA has approved a higher-dose injectable
formulation of the long-acting glucagon-like
peptide-1 (GLP-1) receptor agonist semaglutide
(Ozempic) for treatment of type 2 diabetes in adults.
A single SC injection of the new 8 mg/3 mL
formulation delivers 2 mg of semaglutide.
Semaglutide (Ozempic) for Weight Loss
The Medical Letter on Drugs and Therapeutics • April 5, 2021; (Issue 1621)
In recently published clinical trials, once-weekly
subcutaneous injection of the glucagon-like peptide 1
(GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk), which is FDA-approved for treatment...
In recently published clinical trials, once-weekly
subcutaneous injection of the glucagon-like peptide 1
(GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk), which is FDA-approved for treatment of
type 2 diabetes and to reduce the risk of major adverse
cardiovascular events in adults with type 2 diabetes
and established cardiovascular disease, has reduced
body weight significantly in patients with and without
type 2 diabetes when given in addition to lifestyle
intervention. Liraglutide (Saxenda), another GLP-1
receptor agonist, has been FDA-approved for chronic
weight management since 2015.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • November 4, 2019; (Issue 1584)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of <7% can prevent
microvascular complications (retinopathy, nephropathy,
and neuropathy), but whether it prevents macrovascular
complications and death is unclear. An A1C target of
<8% may be appropriate for older patients and those
with underlying cardiovascular disease (CVD), a history
of severe hypoglycemia, diabetes-related complications,
a limited life expectancy, or a long duration of disease.
Oral Semaglutide (Rybelsus) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • October 21, 2019; (Issue 1583)
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults....
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults. Semaglutide, which has been available in
a subcutaneously-injected formulation (Ozempic)
since 2017, is the first GLP-1 receptor agonist to
become available for oral administration; the 4 other
GLP-1 receptor agonists currently available in the US
are administered by subcutaneous (SC) injection.
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • February 25, 2019; (Issue 1566)
Since 2008, because of safety concerns, the FDA has
mandated that long-term cardiovascular outcomes trials
be conducted for all new drugs for type 2 diabetes.
Reductions in the incidence of macrovascular...
Since 2008, because of safety concerns, the FDA has
mandated that long-term cardiovascular outcomes trials
be conducted for all new drugs for type 2 diabetes.
Reductions in the incidence of macrovascular complications
in these trials with some sodium-glucose
co-transporter 2 (SGLT2) inhibitors and glucagon-like
peptide 1 (GLP-1) receptor agonists in patients at risk
for cardiovascular disease (see Table 1) have led to
new recommendations.
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 29, 2018; (Issue 1539)
The FDA has approved semaglutide (Ozempic – Novo
Nordisk), a long-acting injectable GLP-1 (glucagon-like
peptide-1) receptor agonist, for once-weekly
treatment of adults with type 2 diabetes. It is the...
The FDA has approved semaglutide (Ozempic – Novo
Nordisk), a long-acting injectable GLP-1 (glucagon-like
peptide-1) receptor agonist, for once-weekly
treatment of adults with type 2 diabetes. It is the sixth
GLP-1 receptor agonist to be approved in the US.